ImNIH

ImmuNext is a clinical-stage biotechnology company focused on developing novel immunotherapies that modulate the immune system to treat cancer and autoimmune diseases. The company's technology centers on targeting immune checkpoints, specifically the V-set immunoregulatory receptor (VISTA) and other costimulatory/coinhibitory molecules. ImmuNext has established significant strategic partnerships with major pharmaceutical companies like Janssen, Sanofi, and Curis to advance its pipeline of antibodies and fusion proteins. Their lead programs aim to either stimulate the immune response against tumors or suppress overactive immune responses in chronic inflammatory conditions.